Purchase this article with an account.
J. J. Fromow-Guerra, F. J. Arevalo, H. Quiroz-Mercado, J. G. Sanchez, F. E. Michel, M. H. Berrocal, J. A. Roca, M. J. Saravia, L. Wu, Pan-American Collaborative Retina Study Group(PACORES); Primary Intravitreal Bevacizumab (Avastin) for the Treatment of Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD): Results of the Pan-American Collaborative Retina Study Group (PACORES) at 6-Months Follow-Up. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4569.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)
Interventional retrospective multicenter study in 8 centers from 7 countries in patients with CNV and AMD who were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab. Patients underwent ETDRS testing of BCVA, ophthalmoscopic examination, OCT, and fluorescein angiography (FA) at baseline and follow-up visits. Main outcome measures included changes in BCVA, OCT and FA. Repeated measures analysis of variance was used to compare mean values.
92 eyes of 87 consecutive patients with a mean age of 75.6 ± 8.3 years were included. Mean follow-up 6.8 months (range 6 to 10 months). 46 (50%) eyes needed a second injection at a mean of 9.4 ± 6.2 weeks, fifteen (16.1%) eyes required a third injection at a mean of 9.2 ± 4.0 weeks , and ten (10.9%) eyes required four o more injections. The mean baseline BCVA was logMAR = 1.25 and the final mean BCVA was logMAR = 1.0, (p < 0.0001). Final BCVA showed 33 (35.9%) eyes remained stable, 46 (50%) eyes improved two or more lines, and 13 (14.1%) eyes decreased two or more lines. Mean central macular thickness at baseline by OCT was 345.18 µm ± 154.3 µm and decreased to 257.8 µm ± 94.1 at the end of follow-up (p < 0.0001). Adverse events included transient increased intraocular pressure in 2 (2.2%) eyes, transient hypotony in one (1.1%) eye and endophthalmitis in 2 (2.2%) eyes. No systemic adverse events were observed.
Primary intravitreal bevacizumab at doses of 1.25 mg or 2.5 mg seem to provide stability or improvement in BCVA, OCT and FA in CNV secondary to AMD at 6-months.
This PDF is available to Subscribers Only